The EIF2D Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 colorectal adenocarcinoma cell line, with targeted disruption of the EIF2D gene. This polyclonal knockout pool provides a heterogeneous population of cells carrying diverse loss-of-function mutations in EIF2D, enabling robust functional studies without clonal selection bias. The product is designed for researchers investigating non-canonical translation initiation mechanisms and their roles in cancer biology, particularly in the context of cellular stress responses and therapeutic resistance.
HT29 is a human colorectal adenocarcinoma epithelial cell line isolated from a primary tumor of a 44-year-old Caucasian female. HT29 cells are widely used as an intestinal epithelial model for colon cancer research, known for their well-characterized signaling pathways and their utility in drug response studies. These cells exhibit features of colorectal cancer progression, making them a suitable platform for investigating the molecular drivers of malignancy and the impact of gene knockouts on cancer cell behavior.
EIF2D, also known as Ligatin, functions as a non-canonical translation initiation factor that facilitates ribosome scanning and re-initiation on mRNAs with structured 5?? UTRs, particularly under stress conditions. It forms a complex with DENR and MCTS1 to promote cap-independent translation of stress-responsive mRNAs such as ATF4, MYC, XIAP, BCL2, and CCND1. The activity of EIF2D is regulated by integrated stress response pathways involving eIF2?? kinases (PERK, GCN2) and mTORC1, linking nutrient deprivation, hypoxia, and ER stress to selective mRNA translation. EIF2D interacts with 40S ribosomal subunits, eIF3, eIF1A, and RNA helicases, underscoring its role in ribosome dynamics during translation re-initiation.
In the HT29 colorectal cancer model, disruption of EIF2D offers a valuable tool to dissect the contribution of non-canonical translation to tumor cell adaptation and proliferation. EIF2D-mediated translational control of ATF4 and other stress-responsive factors is implicated in cellular responses to chemotherapeutic agents such as 5-fluorouracil and oxaliplatin, which are commonly used in colorectal cancer treatment. By eliminating EIF2D function, researchers can investigate how altered translation initiation impacts cell viability, apoptosis, migration, and drug sensitivity, providing insights into resistance mechanisms and potential therapeutic vulnerabilities.
This EIF2D knockout polyclonal cell pool supports a wide range of experimental applications. Typical assays include western blotting and RT-qPCR for knockout validation and target gene expression analysis, polysome profiling to assess translation efficiency, dual-luciferase IRES reporter assays for cap-independent translation, cell viability and apoptosis assays (MTT, Annexin V), Transwell migration/invasion assays, and drug sensitivity testing with standard colorectal cancer therapeutics. The model is well-suited for screening translation modulators and dissecting the mTOR-ATF4 signaling axis in cancer. For additional information about this product and its applications, please contact Ascent Research.
